Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus casei ATCC 393
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacticaseibacillus casei ATCC 393 is a specific probiotic bacterial strain, formerly classified as Lactobacillus casei, which serves as the type strain for its species. It is widely utilized in research for its potential therapeutic effects on metabolic and gastrointestinal health. The strain functions primarily by modulating the gut microbiota, promoting the growth of beneficial genera such as Coprococcus and Bacteroides while suppressing potentially harmful taxa. In preclinical models of hyperlipidemia, L. casei ATCC 393 has demonstrated the ability to significantly reduce serum glucose, total cholesterol, and triglycerides, as well as alleviate hepatic lipid accumulation and systemic inflammation (evidenced by reduced IL-6 levels). It is frequently studied in synbiotic combinations with prebiotics like d-tagatose to enhance its metabolic benefits.
- Other names
- Lactobacillus casei ATCC 393L. casei ATCC 393
Beyond the preview
Go deeper on lacticaseibacillus casei ATCC 393.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus casei ATCC 393.